Ono Pharmaceutical Co. (OPHLF) shares closed 10.4% higher at $14.90 in the latest trading session, following positive momentum in investor sentiment regarding its oncology and specialty medicine portfolio. The company’s stock had been down 7.2% over the previous four weeks. Factors contributing to this uptick include regulatory progress for its leading drug Opdivo (nivolumab), development of Velexbru (tirabrutinib), and encouraging mid-stage data from pipeline candidates ONO-4578 and ONO-2808.
In its upcoming quarterly earnings report, Ono is projected to report earnings of $0.23 per share, marking an 11.5% decline year-over-year, with revenues expected to be $695.08 million, down 21.3% from the previous year. The consensus EPS estimate has remained unchanged over the last month, indicating stability in earnings expectations despite recent stock price increases.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
